drugset / Trial / NCT06881264

A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

NCT06881264

Phase 3 Completed 401 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Timeline

Start
2024-04-30
Primary completion
2025-09-19
Completion
2025-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject HR17031 Unknown
Subject insulin glargine Protein / enzyme biologic

Indications

No indication recorded.